Miller Michael Patrick Insider Trading for 1,500 Shares of Jazz Pharmaceuticals plc (JAZZ); Carrols Restaurant Group Has 0.98 Sentiment

Carrols Restaurant Group, Inc. (NASDAQ:TAST) Logo

Sentiment for Carrols Restaurant Group Inc (TAST)

Carrols Restaurant Group Inc (TAST) investors sentiment decreased to 0.98 in Q3 2019. It’s down -0.45, from 1.43 in 2019Q2. The ratio worsened, as 45 institutional investors started new or increased stock positions, while 46 cut down and sold equity positions in Carrols Restaurant Group Inc. The institutional investors in our database now hold: 27.72 million shares, down from 29.54 million shares in 2019Q2. Also, the number of institutional investors holding Carrols Restaurant Group Inc in top ten stock positions increased from 1 to 3 for an increase of 2. Sold All: 16 Reduced: 30 Increased: 30 New Position: 15.

More notable recent Jazz Pharmaceuticals plc (NASDAQ:JAZZ) news were published by: which released: “Is Jazz Pharmaceuticals (JAZZ) Outperforming Other Medical Stocks This Year? – Nasdaq” on December 24, 2019, also with their article: “Do You Like Jazz Pharmaceuticals plc (NASDAQ:JAZZ) At This P/E Ratio? – Yahoo Finance” published on January 02, 2020, published: “PharmaMar And Jazz Pharma Sign License Deal For Lurbinectedin In U.S. – Nasdaq” on December 19, 2019. More interesting news about Jazz Pharmaceuticals plc (NASDAQ:JAZZ) were released by: and their article: “Interesting JAZZ Put And Call Options For February 21st – Nasdaq” published on January 10, 2020 as well as‘s news article titled: “How Did Jazz Pharmaceuticals (JAZZ) Compare Against Top Hedge Fund Stocks in 2019? – Yahoo Finance” with publication date: January 13, 2020.

Analysts await Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to report earnings on February, 25. They expect $3.57 EPS, up 9.17% or $0.30 from last year’s $3.27 per share. JAZZ’s profit will be $198.65M for 10.70 P/E if the $3.57 EPS becomes a reality. After $3.65 actual EPS reported by Jazz Pharmaceuticals plc for the previous quarter, Wall Street now forecasts -2.19% negative EPS growth.

The stock increased 1.67% or $2.51 during the last trading session, reaching $152.74. About 899,790 shares traded or 75.40% up from the average. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has risen 4.15% since January 16, 2019 and is uptrending. It has outperformed by 4.15% the S&P500. Some Historical JAZZ News: 23/03/2018 – JAZZ PHARMACEUTICALS PLC JAZZ.O : H.C. WAINWRIGHT & CO RAISES TARGET PRICE TO $160 FROM $150; 08/05/2018 – JAZZ PHARMA 1Q ADJ EPS $2.98, EST. $2.72; 24/04/2018 – BI UK: Frustrated investors want rare disease drugmaker Jazz to sell its blockbuster sleep business; 14/03/2018 – New Research: Key Drivers of Growth for Jazz Pharmaceuticals, Armstrong World Industries, Banco Latinoamericano de Comercio Ext; 01/05/2018 – Jazz Pharmaceuticals Submits Supplemental New Drug Application for Xyrem® (sodium oxybate) to Treat Cataplexy and Excessive; 22/05/2018 – Moody’s Assigns Ba1 To Jazz Pharma’s Senior Secured Credit Facilities; 08/05/2018 – JAZZ PHARMA SEES FY ADJ EPS $12.75 TO $13.25, EST. $12.82; 15/05/2018 – Jazz Pharma Presenting at Bank of America Conference Tomorrow; 08/05/2018 – Jazz Pharmaceuticals Sees 2018 Rev $1.88B-$1.93B; 01/05/2018 – Jazz Pharmaceuticals Submits Supplemental New Drug Application for Xyrem® (sodium oxybate) to Treat Cataplexy and Excessive Da

The insider of Jazz Pharmaceuticals Plc, Miller Michael Patrick has made a sudden trade in the firm that is worth $220,170 U.S. Dollars. As published in the Security and Exchange Commission public document filed on January 15, 2020, Miller Michael Patrick sold 1,500 shares based on an average market price per share of $146.8. Miller Michael Patrick today owns 0.05% of Jazz Pharmaceuticals Plc’s market capitalization with ownership of 28,071 shares. 

Investors sentiment increased to 1.27 in 2019 Q3. Its up 0.10, from 1.17 in 2019Q2. It improved, as 32 investors sold Jazz Pharmaceuticals plc shares while 102 reduced holdings. 52 funds opened positions while 118 raised stakes. 48.23 million shares or 4.74% less from 50.63 million shares in 2019Q2 were reported. Janney Montgomery Scott Lc holds 4,562 shares or 0% of its portfolio. Charles Schwab Investment Management reported 0.04% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). New York-based Products Prtnrs Ltd Liability Company has invested 0.42% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Gw Henssler Ltd holds 2,700 shares or 0.03% of its portfolio. Price T Rowe Associate Md holds 218,399 shares or 0% of its portfolio. Millennium Mgmt Ltd Liability has invested 0% of its portfolio in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Engineers Gate Manager L P stated it has 0.37% of its portfolio in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Bnp Paribas Arbitrage has invested 0% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Tekla, a Massachusetts-based fund reported 74,936 shares. Parkside Bank & Trust And Tru owns 41 shares. Paloma Prns Mngmt holds 0.01% of its portfolio in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 5,089 shares. National Bank & Trust Of Hawaii holds 0.03% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) or 3,205 shares. Aqr Cap Mngmt Ltd Liability Com, a Connecticut-based fund reported 1.33M shares. 38,736 are owned by Great West Life Assurance Can. Ny State Common Retirement Fund stated it has 114,399 shares or 0.02% of all its holdings.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has market cap of $8.50 billion. The firm has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It has a 14.64 P/E ratio. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain.

Among 4 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Jazz Pharmaceuticals has $20000 highest and $14200 lowest target. $169.50’s average target is 10.97% above currents $152.74 stock price. Jazz Pharmaceuticals had 10 analyst reports since August 21, 2019 according to SRatingsIntel. The company was maintained on Monday, December 2 by Barclays Capital. Wells Fargo maintained the stock with “Outperform” rating in Tuesday, December 3 report. Piper Jaffray downgraded it to “Neutral” rating and $14200 target in Wednesday, August 21 report. Bernstein maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Monday, October 14 with “Market Perform” rating.

Since December 9, 2019, it had 0 buys, and 1 sale for $223,680 activity. MILLER MICHAEL PATRICK sold $223,680 worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Monday, December 9.

The stock decreased 5.69% or $0.33 during the last trading session, reaching $5.47. About 2.19M shares traded or 263.17% up from the average. Carrols Restaurant Group, Inc. (TAST) has declined 33.12% since January 16, 2019 and is downtrending. It has underperformed by 33.12% the S&P500. Some Historical TAST News: 08/05/2018 – CARROLS RESTAURANT GROUP INC – ADJUSTED EBITDA IS NOW EXPECTED TO BE $95 MLN TO $102 MLN FOR 2018; 21/04/2018 – DJ Carrols Restaurant Group Inc, Inst Holders, 1Q 2018 (TAST); 08/05/2018 – CARROLS RESTAURANT GROUP INC – QTRLY COMPARABLE RESTAURANT SALES INCREASED 6.2% VS 0.6% DECREASE IN PRIOR YEAR QUARTER; 08/05/2018 – Carrols Restaurant Sees 2018 Commodity Costs Up 1% to 2%; 08/05/2018 – Carrols Restaurant Sees 2018 Total Restaurant Sales $1.15B-$1.17B; 16/05/2018 – Carrols Restaurant Closes Below 200-Day Average: Technicals; 08/05/2018 – CARROLS RESTAURANT GROUP -2018 TOTAL RESTAURANT SALES EXPECTED TO BE $1.15 BLN – $1.17 BLN INCLUDING COMPARABLE RESTAURANT SALES INCREASE OF 3%- 5%; 08/05/2018 – Carrols Restaurant Sees 2018 Beef Costs Up 2% to 3%; 14/05/2018 – Wallace Capital Management Inc. Exits Carrols Restaurant; 08/05/2018 – Carrols Restaurant Sees 2018 Capex $50M-$60M

Carrols Restaurant Group, Inc., through its subsidiaries, operates franchisee restaurants of Burger King. The company has market cap of $283.61 million. As of March 2, 2017, it operated 790 Burger King restaurants in the United States. It currently has negative earnings.

More notable recent Carrols Restaurant Group, Inc. (NASDAQ:TAST) news were published by: which released: “Investors In These 2 Stocks Should Heed a Warning from Burger King Franchisee’s Results – Nasdaq” on January 16, 2020, also with their article: “Carrols Restaurant -12% after comparable sales decelerate – Seeking Alpha” published on January 13, 2020, published: “Popeyes’ Chicken Sandwich War Paid Off In A Huge Way For Franchisees – Benzinga” on January 14, 2020. More interesting news about Carrols Restaurant Group, Inc. (NASDAQ:TAST) were released by: and their article: “Stocks That Hit 52-Week Lows On Wednesday – Benzinga” published on January 15, 2020 as well as‘s news article titled: “Carrols Restaurant a favorite at Stephens – Seeking Alpha” with publication date: January 02, 2020.

Cannell Capital Llc holds 7.07% of its portfolio in Carrols Restaurant Group, Inc. for 2.63 million shares. Private Capital Management Llc owns 2.81 million shares or 4.06% of their US portfolio. Moreover, Cooper Creek Partners Management Llc has 3.76% invested in the company for 1.29 million shares. The Pennsylvania-based Millrace Asset Group Inc. has invested 3.02% in the stock. Cove Street Capital Llc, a California-based fund reported 810,700 shares.

Carrols Restaurant Group, Inc. (NASDAQ:TAST) Institutional Positions Chart